Recursion Pharmaceuticals, Inc. (RXRX) stock surged 12.63% in the pre-market trading session on Tuesday, following Nvidia's disclosure that it maintained its investment in the medical AI company during the fourth quarter of 2024.
According to regulatory filings, Nvidia revealed that it held on to its stake in Recursion Pharmaceuticals, a move that has bolstered investor confidence in the company's prospects. This sustained backing from the tech giant has fueled the pre-market rally, as traders view Nvidia's continued investment as a vote of confidence in Recursion Pharmaceuticals' potential.
The positive sentiment surrounding Recursion Pharmaceuticals was further amplified by Berkshire Hathaway's recent investment activities, including taking a new position in Constellation Brands, a move that has injected optimism into the broader market.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。